Buy Sitagliptin

Sitagliptin

Sitagliptin: Comprehensive Overview for Adults

Introduction

Sitagliptin is a prescription medication used to improve blood-glucose control in adults with type 2 diabetes mellitus (T2DM). The active ingredient is sitagliptin phosphate, sold in a pill formulation. In the United Kingdom, it is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is available only with a prescription. The product is marketed in strengths of 50 mg and 100 mg per tablet.

How Sitagliptin Works in the Body

Sitagliptin belongs to the class of dipeptidyl-peptidase-4 (DPP-4) inhibitors. DPP-4 is an enzyme that rapidly breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, sitagliptin prolongs the activity of these hormones, leading to:

• Increased insulin secretion from pancreatic β-cells when blood glucose is elevated.
• Reduced glucagon release from pancreatic α-cells, decreasing hepatic glucose production.

These actions help lower post-prandial (after-meal) glucose levels without causing significant hypoglycaemia when used alone. Sitagliptin is absorbed quickly after oral administration, reaching peak plasma concentrations within 2-4 hours. It is primarily excreted unchanged by the kidneys; therefore, renal function influences dosing.

Conditions Treated by Sitagliptin

In the UK, sitagliptin is licensed for the treatment of type 2 diabetes when diet, exercise, and other oral agents (e.g., metformin) do not achieve adequate glycaemic control. It may be prescribed as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or basal insulin. The medication is not indicated for type 1 diabetes, gestational diabetes, or diabetic ketoacidosis.

Patient Suitability and Contraindications

Who May Benefit

• Adults with type 2 diabetes whose HbA1c target is not met with first-line therapy.
• Individuals who require an oral agent with a low intrinsic risk of hypoglycaemia.

Absolute Contraindications

• Known hypersensitivity to sitagliptin phosphate or any excipients in the tablet.
• History of type 1 diabetes mellitus or diabetic ketoacidosis.

Relative Contraindications / Cautions

• Severe renal impairment (eGFR < 30 mL/min/1.73 m²): sitagliptin is not recommended.
• Moderate renal impairment (eGFR 30-45 mL/min/1.73 m²): dose should be reduced to 50 mg once daily.
• Hepatic impairment: no dose adjustment is required, but caution is advised.
• Pregnancy and lactation: sitagliptin is category B3 in the UK; it should only be used if the potential benefit outweighs the risk.
• Elderly patients: start with the lower dose (50 mg) and monitor renal function closely.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Upper respiratory tract infection - mild, self-limiting.
• Headache - often transient.
• Nasopharyngitis - sore throat or nasal congestion.
• Gastro-intestinal discomfort (e.g., nausea, diarrhoea) - usually mild.

Serious Adverse Events

• Pancreatitis - rare but potentially severe; patients should seek medical attention for persistent abdominal pain.
• Severe hypersensitivity reactions (e.g., angio-edema, Stevens-Johnson syndrome).
• Joint pain - reports of severe, debilitating arthralgia have led to a rare FDA safety communication; monitor for unexplained musculoskeletal pain.

Drug Interactions

• Insulin or sulfonylureas - additive glucose-lowering effect; increased risk of hypoglycaemia. Dose adjustment of the concomitant agent may be needed.
• Strong CYP2C8 inhibitors (e.g., gemfibrozil) - can raise sitagliptin plasma concentrations; monitor for side effects.
• Diuretics (especially thiazides) - may increase the risk of dehydration and renal impairment, indirectly affecting sitagliptin clearance.

Because sitagliptin is largely excreted unchanged, interactions via metabolic pathways are limited, but clinicians should review all concurrent medicines, including over-the-counter products and herbal supplements.

Food and Lifestyle Interactions

• Sitagliptin may be taken with or without food; food does not markedly affect its absorption.
• Alcohol does not directly interact, but excessive intake can worsen glycaemic control and increase hypoglycaemia risk when combined with insulin or sulfonylureas.
• No known impairment of driving or use of machinery.

Dosing and Administration Guidelines

Standard Dosing

• Initial dose: 100 mg once daily for most adults with normal renal function.
• Renal adjustment: 50 mg once daily if eGFR 30-45 mL/min/1.73 m²; sitagliptin is not recommended when eGFR < 30 mL/min/1.73 m².

Special Populations

• Elderly patients: consider starting at 50 mg once daily, especially if renal function is uncertain.
• Patients with moderate hepatic impairment: no dose change required, but monitor liver enzymes if clinically indicated.

Administration Tips

• Swallow the tablet whole with a glass of water.
• Do not crush, chew, or split the tablet unless specifically advised by a pharmacist.
• Take the medication at the same time each day to maintain consistent plasma levels.

Missed Dose

• If a dose is missed, take it as soon as remembered unless it is close to the time of the next scheduled dose. In that case, skip the missed dose; do not double-dose.

Overdose

• Symptoms may include severe nausea, vomiting, and hypoglycaemia (if combined with other glucose-lowering agents).
• Seek immediate medical attention; supportive care and monitoring are the mainstays of treatment. No specific antidote exists.

Discontinuation

• Sitagliptin can be stopped abruptly without tapering.
• If transitioning to another antidiabetic regimen, coordinate with a healthcare professional to avoid gaps in glycaemic control.

Monitoring and Follow-Up

• HbA1c should be measured every 3-6 months to assess efficacy.
• Renal function (eGFR) should be evaluated at baseline and at least annually, more frequently in patients with known kidney disease.
• Pancreatic enzymes (amylase, lipase) are not routinely required but should be measured if pancreatitis is suspected.
• Blood glucose self-monitoring may be advised when sitagliptin is combined with insulin or sulfonylureas.

Storage and Handling

• Store tablets at room temperature (15-30 °C), protected from moisture and direct sunlight.
• Keep out of reach of children; consider a child-resistant container.
• Do not use tablets beyond the expiry date printed on the packaging.
• Dispose of unused medication in accordance with local pharmacy take-back programmes or the NHS guidelines for safe drug disposal.

Medication-Specific Glossary

DPP-4 Inhibitor

A drug class that blocks the enzyme dipeptidyl-peptidase-4, prolonging the action of incretin hormones and enhancing glucose-dependent insulin secretion.

GLP-1 (Glucagon-Like Peptide-1)

An incretin hormone released after meals that stimulates insulin release, suppresses glucagon, and slows gastric emptying.

HbA1c

Glycated haemoglobin; reflects average blood glucose over the previous 2-3 months and is used to gauge long-term diabetes control.

eGFR (Estimated Glomerular Filtration Rate)

A calculated measure of kidney function; essential for dosing adjustments of renally excreted drugs such as sitagliptin.

Pancreatitis

Inflammation of the pancreas; a rare but serious adverse effect that can present with upper abdominal pain, nausea, and elevated pancreatic enzymes.

Medical Disclaimer

This article provides educational information about sitagliptin and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.